Thus, in cells where any of the genes are mutated that are necessary for anthracyclines’ induction of LIICD (e.g., p53, caspase, BAX, etc.), these drugs will be ineffective at causing the appropriate cytotoxicity of tumor cells and anticancer immune response. The gene discussed is TP53; the disease is neoplasm.